Opal Capital LLC Invests $3.07 Million in IDEXX Laboratories, Inc. $IDXX

Opal Capital LLC bought a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 1st quarter, Holdings Channel.com reports. The firm bought 5,458 shares of the company’s stock, valued at approximately $3,067,000.

A number of other institutional investors have also recently added to or reduced their stakes in IDXX. Empowered Funds LLC boosted its position in shares of IDEXX Laboratories by 6.6% in the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock worth $646,000 after buying an additional 95 shares during the period. Sivia Capital Partners LLC purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at about $265,000. Jump Financial LLC raised its holdings in shares of IDEXX Laboratories by 1,006.4% during the 2nd quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock valued at $2,967,000 after buying an additional 5,032 shares during the period. Cary Street Partners Financial LLC acquired a new position in IDEXX Laboratories during the 2nd quarter worth approximately $164,000. Finally, Sei Investments Co. boosted its holdings in IDEXX Laboratories by 218.7% in the 2nd quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock worth $64,678,000 after acquiring an additional 82,755 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on IDXX shares. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. UBS Group reduced their target price on shares of IDEXX Laboratories from $640.00 to $620.00 and set a “neutral” rating on the stock in a research report on Monday. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Citigroup started coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target for the company. Finally, Stifel Nicolaus dropped their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average target price of $749.00.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $569.54 on Wednesday. IDEXX Laboratories, Inc. has a fifty-two week low of $518.55 and a fifty-two week high of $769.98. The business has a 50 day moving average price of $556.94 and a two-hundred day moving average price of $592.72. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The firm has a market cap of $44.93 billion, a PE ratio of 41.94, a price-to-earnings-growth ratio of 3.04 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the business earned $2.91 EPS. IDEXX Laboratories’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.